pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$FATEFATE THERAPEUTICS INC

$FATE
San Diego, CA, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
8
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(8)

pipeline depth8 products
Preclinical: 3Phase 1: 5
3Preclinical5Phase 1
Phase 1
FT-522
B-Cell Non-Hodgkin Lymphoma
Phase 1
FT-576
Refractory Multiple Myeloma
Phase 1
FT-819
Idiopathic Inflammatory Myopathy (IIM)
Phase 1
FT-825
Colorectal Cancer
Phase 1
FT-836
Breast Cancer
Preclinical
FT-839
Hematological Tumor
Preclinical
FT-8XX
Unspecified Cancer
Preclinical
Undisclosed
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritisnot yet recruitingn=53
  • phase1FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumorsrecruitingn=113
  • phase1FT819 in Subjects With B-cell Malignanciesactive not recruitingn=54
  • phase1A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Diseaserecruitingn=244
  • phase1FT576 in Subjects With Multiple Myelomacompletedn=31
  • phase1FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumorsrecruitingn=351
  • phase1FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)completedn=20
  • phase1FT516 in Subjects With Advanced Hematologic Malignanciesterminatedn=72
more trials →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Apr 20, 26otherRedmile Group, LLC · 8,977,624 sh
  • Apr 20, 26otherRedmile Group, LLC · 8,977,624 sh
  • Apr 20, 26otherRedmile Group, LLC · 3,691,324 sh
  • Apr 20, 26otherRedmile Group, LLC · 3,691,324 sh
  • Apr 20, 26otherRedmile Group, LLC · 266,280 sh
  • Apr 20, 26otherRedmile Group, LLC · 266,280 sh
🐶 Hiring Signal
No open roles indexed yet — view FATE THERAPEUTICS INC jobs →

News

  • Scribe’s early-stage IPO standout defies biotech’s derisking trend
    Scribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.
    biospace · 13h ago
  • Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
    “Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.
    stat · 19h ago
  • Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
    Following a phase 3 knee osteoarthritis failure that its CEO acknowledged caused “great disappointment and concern,” Kolon TissueGene is laying off 37 employees at its Maryland headquarters.
    fiercebiotech · 2d ago
  • Capricor soars on potential FDA review extension, filing amendments
    Capricor Therapeutics’ CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel, with the…
    biospace · 6d ago
  • Key Senate panel backs Trump’s picks for CDC, pandemic preparedness
    In win for RFK Jr., Senate committee sends nominations of Erica Schwartz for CDC director and Sean Kaufman for ASPR to full Senate.
    stat · 21d ago
  • FDA reminds investors about the risks of advisory panels
    Two days, two similar briefing documents and two companies with diving share prices. The FDA this week laid out its concerns with clinical data from both Capricor Therapeutics and
    endpoints · 23d ago
  • STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
    Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.
    stat · 23d ago
  • Sarepta names former AbbVie R&D exec Michael Severino as next CEO
    After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.
    biospace · 24d ago
  • FDA panel confronting peptide controversy
    Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
    stat · 28d ago
  • STAT+: At key hearing, Kennedy’s ouster of former CDC director looms over nominee to replace her
    Erica Schwartz and Sean Kaufman navigated tough questions about vaccines, political independence, and pushing back on RFK Jr.
    stat · 1mo ago
view all news mentions →
identifiers
ticker
$FATE
SEC CIK
0001434316
country
US
source
sec_tickers
top tags
Oncology8Immunology3Colorectal Cancer2NSCLC2Breast Cancer1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed just now
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?